Why the study?
Do therapies targeting inflammatory processes reduce myocardial reperfusion injury in patients with acute myocardial infarction?
Do therapies targeting inflammatory processes reduce myocardial reperfusion injury in patients with acute myocardial infarction?
Targeting the inflammatory response, particularly chemokine secretion, represents a promising therapeutic avenue to mitigate reperfusion injury following acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
May support chemokine modulation to limit reperfusion injury; hypothesis-generating from Level 5 review and needs prospective trials.
Acute myocardial infarction is the leading cause of morbidity and mortality in the adult population of developed and developing nations. Although the prompt restoration of antegrade blood flow in the infarct-related coronary artery is the mean therapy for improving survival, reperfusion itself may cause damage to ischaemic myocardial tissue. This event is well known as "reperfusion injury". Crucial mediators for cardiac damage in the reperfusion phases are oxidative stress, inflammation and leukocyte infiltration. Already approved and novel therapies might directly reduce these inflammatory processes. Treatments modulating chemokine secretion and activity should be considered as very promising approaches to reduce myocardial reperfusion injury.
No takes yet. Share an insight, caveat, or question.
Steffens et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: